Reports Q4 revenue $10.24B, consensus $10.18B. “The strength and diversity of the Abbott portfolio drove our success in 2023,” said Robert B. Ford, chairman and chief executive officer, Abbott. “We’re entering 2024 with a lot of positive momentum, and with our highly productive pipeline, we’re well-positioned for growth in 2024 and beyond.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Options Volatility and Implied Earnings Moves Today, January 24, 2024
- Options Volatility and Implied Earnings Moves This Week, January 22 – January 26, 2024
- Abbott Laboratories (ABT) Q4 Earnings Cheat Sheet
- Abbott announces first procedures using its Volt Pulsed Field Ablation
- Abbott price target raised to $131 from $121 at Wells Fargo